|

MCLA-158 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: petosemtamab

Pipeline

Phase 1/2: 1

Top Sponsors

  • Merus B.V.1

Indications

  • Advanced/Metastatic Solid Tumors1
  • HNSCC1
  • Head and Neck Squamous Cell Carcinoma1
  • NSCLC1
  • Colorectal Cancer1

La Jolla, California1 trial

A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors

UCSD

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.